#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0004] 2.
1-1	0-1	[	_	_	
1-2	1-5	0004	_	_	
1-3	5-6	]	_	_	
1-4	7-8	2	_	_	
1-5	8-9	.	_	_	

#Text=Description of the Related Art
#Text=[0005] Subcutaneous injection is a standard method for the delivery of medication into a patient's body.
2-1	10-21	Description	_	_	
2-2	22-24	of	_	_	
2-3	25-28	the	_	_	
2-4	29-36	Related	_	_	
2-5	37-40	Art	_	_	
2-6	41-42	[	_	_	
2-7	42-46	0005	_	_	
2-8	46-47	]	_	_	
2-9	48-60	Subcutaneous	_	_	
2-10	61-70	injection	_	_	
2-11	71-73	is	_	_	
2-12	74-75	a	_	_	
2-13	76-84	standard	_	_	
2-14	85-91	method	_	_	
2-15	92-95	for	_	_	
2-16	96-99	the	_	_	
2-17	100-108	delivery	_	_	
2-18	109-111	of	_	_	
2-19	112-122	medication	_	_	
2-20	123-127	into	_	_	
2-21	128-129	a	_	_	
2-22	130-139	patient's	_	_	
2-23	140-144	body	_	_	
2-24	144-145	.	_	_	

#Text=To facilitate frequent or continuous subcutaneous injection of medication, subcutaneous injection ports are often used.
3-1	146-148	To	_	_	
3-2	149-159	facilitate	_	_	
3-3	160-168	frequent	_	_	
3-4	169-171	or	_	_	
3-5	172-182	continuous	_	_	
3-6	183-195	subcutaneous	_	_	
3-7	196-205	injection	_	_	
3-8	206-208	of	_	_	
3-9	209-219	medication	_	_	
3-10	219-220	,	_	_	
3-11	221-233	subcutaneous	_	_	
3-12	234-243	injection	_	_	
3-13	244-249	ports	_	_	
3-14	250-253	are	_	_	
3-15	254-259	often	_	_	
3-16	260-264	used	_	_	
3-17	264-265	.	_	_	

#Text=Such injection ports extend through the skin and may remain in place for several days.
4-1	266-270	Such	_	_	
4-2	271-280	injection	_	_	
4-3	281-286	ports	_	_	
4-4	287-293	extend	_	_	
4-5	294-301	through	_	_	
4-6	302-305	the	_	_	
4-7	306-310	skin	_	_	
4-8	311-314	and	_	_	
4-9	315-318	may	_	_	
4-10	319-325	remain	_	_	
4-11	326-328	in	_	_	
4-12	329-334	place	_	_	
4-13	335-338	for	_	_	
4-14	339-346	several	_	_	
4-15	347-351	days	_	_	
4-16	351-352	.	_	_	

#Text=Currently, a major application of such injection ports is to provide continuous delivery of medication, such as insulin, from portable pumps carried with the patient.
5-1	353-362	Currently	_	_	
5-2	362-363	,	_	_	
5-3	364-365	a	_	_	
5-4	366-371	major	_	_	
5-5	372-383	application	_	_	
5-6	384-386	of	_	_	
5-7	387-391	such	_	_	
5-8	392-401	injection	_	_	
5-9	402-407	ports	_	_	
5-10	408-410	is	_	_	
5-11	411-413	to	_	_	
5-12	414-421	provide	_	_	
5-13	422-432	continuous	_	_	
5-14	433-441	delivery	_	_	
5-15	442-444	of	_	_	
5-16	445-455	medication	_	_	
5-17	455-456	,	_	_	
5-18	457-461	such	_	_	
5-19	462-464	as	_	_	
5-20	465-472	insulin	_	_	
5-21	472-473	,	_	_	
5-22	474-478	from	_	_	
5-23	479-487	portable	_	_	
5-24	488-493	pumps	_	_	
5-25	494-501	carried	_	_	
5-26	502-506	with	_	_	
5-27	507-510	the	_	_	
5-28	511-518	patient	_	_	
5-29	518-519	.	_	_	

#Text=When used with a portable pump, the injection port is typically connected to the pump via a fluid line.
6-1	520-524	When	_	_	
6-2	525-529	used	_	_	
6-3	530-534	with	_	_	
6-4	535-536	a	_	_	
6-5	537-545	portable	_	_	
6-6	546-550	pump	_	_	
6-7	550-551	,	_	_	
6-8	552-555	the	_	_	
6-9	556-565	injection	_	_	
6-10	566-570	port	_	_	
6-11	571-573	is	_	_	
6-12	574-583	typically	_	_	
6-13	584-593	connected	_	_	
6-14	594-596	to	_	_	
6-15	597-600	the	_	_	
6-16	601-605	pump	_	_	
6-17	606-609	via	_	_	
6-18	610-611	a	_	_	
6-19	612-617	fluid	_	_	
6-20	618-622	line	_	_	
6-21	622-623	.	_	_	

#Text=Another application of subcutaneous injection ports is to permit multiple injections of medication into a patient without the need to re-puncture the patient's skin.
7-1	624-631	Another	_	_	
7-2	632-643	application	_	_	
7-3	644-646	of	_	_	
7-4	647-659	subcutaneous	_	_	
7-5	660-669	injection	_	_	
7-6	670-675	ports	_	_	
7-7	676-678	is	_	_	
7-8	679-681	to	_	_	
7-9	682-688	permit	_	_	
7-10	689-697	multiple	_	_	
7-11	698-708	injections	_	_	
7-12	709-711	of	_	_	
7-13	712-722	medication	_	_	
7-14	723-727	into	_	_	
7-15	728-729	a	_	_	
7-16	730-737	patient	_	_	
7-17	738-745	without	_	_	
7-18	746-749	the	_	_	
7-19	750-754	need	_	_	
7-20	755-757	to	_	_	
7-21	758-769	re-puncture	_	_	
7-22	770-773	the	_	_	
7-23	774-783	patient's	_	_	
7-24	784-788	skin	_	_	
7-25	788-789	.	_	_	

#Text=In this application, medication is injected from a standard medical implement, such as a syringe, through a soft elastomer septum into the injection port which delivers the medication subcutaneously.
#Text=[0006] Subcutaneous injection ports generally require a sharp, rigid needle to pierce the patient's skin when initially attached to the patient.
8-1	790-792	In	_	_	
8-2	793-797	this	_	_	
8-3	798-809	application	_	_	
8-4	809-810	,	_	_	
8-5	811-821	medication	_	_	
8-6	822-824	is	_	_	
8-7	825-833	injected	_	_	
8-8	834-838	from	_	_	
8-9	839-840	a	_	_	
8-10	841-849	standard	_	_	
8-11	850-857	medical	_	_	
8-12	858-867	implement	_	_	
8-13	867-868	,	_	_	
8-14	869-873	such	_	_	
8-15	874-876	as	_	_	
8-16	877-878	a	_	_	
8-17	879-886	syringe	_	_	
8-18	886-887	,	_	_	
8-19	888-895	through	_	_	
8-20	896-897	a	_	_	
8-21	898-902	soft	_	_	
8-22	903-912	elastomer	_	_	
8-23	913-919	septum	_	_	
8-24	920-924	into	_	_	
8-25	925-928	the	_	_	
8-26	929-938	injection	_	_	
8-27	939-943	port	_	_	
8-28	944-949	which	_	_	
8-29	950-958	delivers	_	_	
8-30	959-962	the	_	_	
8-31	963-973	medication	_	_	
8-32	974-988	subcutaneously	_	_	
8-33	988-989	.	_	_	
8-34	990-991	[	_	_	
8-35	991-995	0006	_	_	
8-36	995-996	]	_	_	
8-37	997-1009	Subcutaneous	_	_	
8-38	1010-1019	injection	_	_	
8-39	1020-1025	ports	_	_	
8-40	1026-1035	generally	_	_	
8-41	1036-1043	require	_	_	
8-42	1044-1045	a	_	_	
8-43	1046-1051	sharp	_	_	
8-44	1051-1052	,	_	_	
8-45	1053-1058	rigid	_	_	
8-46	1059-1065	needle	_	_	
8-47	1066-1068	to	_	_	
8-48	1069-1075	pierce	_	_	
8-49	1076-1079	the	_	_	
8-50	1080-1089	patient's	_	_	
8-51	1090-1094	skin	_	_	
8-52	1095-1099	when	_	_	
8-53	1100-1109	initially	_	_	
8-54	1110-1118	attached	_	_	
8-55	1119-1121	to	_	_	
8-56	1122-1125	the	_	_	
8-57	1126-1133	patient	_	_	
8-58	1133-1134	.	_	_	

#Text=However, in some applications, if the needle were left in place through the skin to provide medication delivery, after one or two days the needle could become uncomfortable to the patient.
9-1	1135-1142	However	*[1]	10-3[2_1]	
9-2	1142-1143	,	*[1]	_	
9-3	1144-1146	in	*[1]	_	
9-4	1147-1151	some	*[1]	_	
9-5	1152-1164	applications	*[1]	_	
9-6	1164-1165	,	*[1]	_	
9-7	1166-1168	if	*[1]	_	
9-8	1169-1172	the	*[1]	_	
9-9	1173-1179	needle	*[1]	_	
9-10	1180-1184	were	*[1]	_	
9-11	1185-1189	left	*[1]	_	
9-12	1190-1192	in	*[1]	_	
9-13	1193-1198	place	*[1]	_	
9-14	1199-1206	through	*[1]	_	
9-15	1207-1210	the	*[1]	_	
9-16	1211-1215	skin	*[1]	_	
9-17	1216-1218	to	*[1]	_	
9-18	1219-1226	provide	*[1]	_	
9-19	1227-1237	medication	*[1]	_	
9-20	1238-1246	delivery	*[1]	_	
9-21	1246-1247	,	*[1]	_	
9-22	1248-1253	after	*[1]	_	
9-23	1254-1257	one	*[1]	_	
9-24	1258-1260	or	*[1]	_	
9-25	1261-1264	two	*[1]	_	
9-26	1265-1269	days	*[1]	_	
9-27	1270-1273	the	*[1]	_	
9-28	1274-1280	needle	*[1]	_	
9-29	1281-1286	could	*[1]	_	
9-30	1287-1293	become	*[1]	_	
9-31	1294-1307	uncomfortable	*[1]	_	
9-32	1308-1310	to	*[1]	_	
9-33	1311-1314	the	*[1]	_	
9-34	1315-1322	patient	*[1]	_	
9-35	1322-1323	.	*[1]	_	

#Text=To solve this problem, infusion sets with removable needles and soft plastic cannula to be placed inside the body of a patient have been developed.
10-1	1324-1326	To	_	_	
10-2	1327-1332	solve	_	_	
10-3	1333-1337	this	*[2]	_	
10-4	1338-1345	problem	*[2]	_	
10-5	1345-1346	,	_	_	
10-6	1347-1355	infusion	_	_	
10-7	1356-1360	sets	_	_	
10-8	1361-1365	with	_	_	
10-9	1366-1375	removable	_	_	
10-10	1376-1383	needles	_	_	
10-11	1384-1387	and	_	_	
10-12	1388-1392	soft	_	_	
10-13	1393-1400	plastic	_	_	
10-14	1401-1408	cannula	_	_	
10-15	1409-1411	to	_	_	
10-16	1412-1414	be	_	_	
10-17	1415-1421	placed	_	_	
10-18	1422-1428	inside	_	_	
10-19	1429-1432	the	_	_	
10-20	1433-1437	body	_	_	
10-21	1438-1440	of	_	_	
10-22	1441-1442	a	_	_	
10-23	1443-1450	patient	_	_	
10-24	1451-1455	have	_	_	
10-25	1456-1460	been	_	_	
10-26	1461-1470	developed	_	_	
10-27	1470-1471	.	_	_	

#Text=However, these sets have many disadvantages.
11-1	1472-1479	However	_	_	
11-2	1479-1480	,	_	_	
11-3	1481-1486	these	_	_	
11-4	1487-1491	sets	_	_	
11-5	1492-1496	have	_	_	
11-6	1497-1501	many	_	_	
11-7	1502-1515	disadvantages	_	_	
11-8	1515-1516	.	_	_	

#Text=There remains a need for an improved infusion set that is less bulky, less susceptible to contamination, more comfortable to a user, and easier to use.
#Text=[0007] Some embodiments of the present invention provide an infusion set comprising a base member, an introducer cap, and an infusion cap.
12-1	1517-1522	There	_	_	
12-2	1523-1530	remains	_	_	
12-3	1531-1532	a	_	_	
12-4	1533-1537	need	_	_	
12-5	1538-1541	for	_	_	
12-6	1542-1544	an	_	_	
12-7	1545-1553	improved	_	_	
12-8	1554-1562	infusion	_	_	
12-9	1563-1566	set	_	_	
12-10	1567-1571	that	_	_	
12-11	1572-1574	is	_	_	
12-12	1575-1579	less	_	_	
12-13	1580-1585	bulky	_	_	
12-14	1585-1586	,	_	_	
12-15	1587-1591	less	_	_	
12-16	1592-1603	susceptible	_	_	
12-17	1604-1606	to	_	_	
12-18	1607-1620	contamination	_	_	
12-19	1620-1621	,	_	_	
12-20	1622-1626	more	_	_	
12-21	1627-1638	comfortable	_	_	
12-22	1639-1641	to	_	_	
12-23	1642-1643	a	_	_	
12-24	1644-1648	user	_	_	
12-25	1648-1649	,	_	_	
12-26	1650-1653	and	_	_	
12-27	1654-1660	easier	_	_	
12-28	1661-1663	to	_	_	
12-29	1664-1667	use	_	_	
12-30	1667-1668	.	_	_	
12-31	1669-1670	[	_	_	
12-32	1670-1674	0007	_	_	
12-33	1674-1675	]	_	_	
12-34	1676-1680	Some	_	_	
12-35	1681-1692	embodiments	_	_	
12-36	1693-1695	of	_	_	
12-37	1696-1699	the	_	_	
12-38	1700-1707	present	_	_	
12-39	1708-1717	invention	_	_	
12-40	1718-1725	provide	_	_	
12-41	1726-1728	an	_	_	
12-42	1729-1737	infusion	_	_	
12-43	1738-1741	set	_	_	
12-44	1742-1752	comprising	_	_	
12-45	1753-1754	a	_	_	
12-46	1755-1759	base	_	_	
12-47	1760-1766	member	_	_	
12-48	1766-1767	,	_	_	
12-49	1768-1770	an	_	_	
12-50	1771-1781	introducer	_	_	
12-51	1782-1785	cap	_	_	
12-52	1785-1786	,	_	_	
12-53	1787-1790	and	_	_	
12-54	1791-1793	an	_	_	
12-55	1794-1802	infusion	_	_	
12-56	1803-1806	cap	_	_	
12-57	1806-1807	.	_	_	

#Text=The base member preferably comprises a port on a first side thereof, and a soft cannula extending from a second side of the base member.
13-1	1808-1811	The	_	_	
13-2	1812-1816	base	_	_	
13-3	1817-1823	member	_	_	
13-4	1824-1834	preferably	_	_	
13-5	1835-1844	comprises	_	_	
13-6	1845-1846	a	_	_	
13-7	1847-1851	port	_	_	
13-8	1852-1854	on	_	_	
13-9	1855-1856	a	_	_	
13-10	1857-1862	first	_	_	
13-11	1863-1867	side	_	_	
13-12	1868-1875	thereof	_	_	
13-13	1875-1876	,	_	_	
13-14	1877-1880	and	_	_	
13-15	1881-1882	a	_	_	
13-16	1883-1887	soft	_	_	
13-17	1888-1895	cannula	_	_	
13-18	1896-1905	extending	_	_	
13-19	1906-1910	from	_	_	
13-20	1911-1912	a	_	_	
13-21	1913-1919	second	_	_	
13-22	1920-1924	side	_	_	
13-23	1925-1927	of	_	_	
13-24	1928-1931	the	_	_	
13-25	1932-1936	base	_	_	
13-26	1937-1943	member	_	_	
13-27	1943-1944	.	_	_	

#Text=The port is configured to be in fluid communication with the cannula.
14-1	1945-1948	The	_	_	
14-2	1949-1953	port	_	_	
14-3	1954-1956	is	_	_	
14-4	1957-1967	configured	_	_	
14-5	1968-1970	to	_	_	
14-6	1971-1973	be	_	_	
14-7	1974-1976	in	_	_	
14-8	1977-1982	fluid	_	_	
14-9	1983-1996	communication	_	_	
14-10	1997-2001	with	_	_	
14-11	2002-2005	the	_	_	
14-12	2006-2013	cannula	_	_	
14-13	2013-2014	.	_	_	

#Text=The port also comprises a septum adapted to seal the port against unwanted fluid flow.
15-1	2015-2018	The	_	_	
15-2	2019-2023	port	_	_	
15-3	2024-2028	also	_	_	
15-4	2029-2038	comprises	_	_	
15-5	2039-2040	a	_	_	
15-6	2041-2047	septum	_	_	
15-7	2048-2055	adapted	_	_	
15-8	2056-2058	to	_	_	
15-9	2059-2063	seal	_	_	
15-10	2064-2067	the	_	_	
15-11	2068-2072	port	_	_	
15-12	2073-2080	against	_	_	
15-13	2081-2089	unwanted	_	_	
15-14	2090-2095	fluid	_	_	
15-15	2096-2100	flow	_	_	
15-16	2100-2101	.	_	_	

#Text=The introducer cap is adapted to be mounted to the base member and has a needle adapted to extend through the septum and said soft cannula in an assembled position.
16-1	2102-2105	The	_	_	
16-2	2106-2116	introducer	_	_	
16-3	2117-2120	cap	_	_	
16-4	2121-2123	is	_	_	
16-5	2124-2131	adapted	_	_	
16-6	2132-2134	to	_	_	
16-7	2135-2137	be	_	_	
16-8	2138-2145	mounted	_	_	
16-9	2146-2148	to	_	_	
16-10	2149-2152	the	_	_	
16-11	2153-2157	base	_	_	
16-12	2158-2164	member	_	_	
16-13	2165-2168	and	_	_	
16-14	2169-2172	has	_	_	
16-15	2173-2174	a	_	_	
16-16	2175-2181	needle	_	_	
16-17	2182-2189	adapted	_	_	
16-18	2190-2192	to	_	_	
16-19	2193-2199	extend	_	_	
16-20	2200-2207	through	_	_	
16-21	2208-2211	the	_	_	
16-22	2212-2218	septum	_	_	
16-23	2219-2222	and	_	_	
16-24	2223-2227	said	_	_	
16-25	2228-2232	soft	_	_	
16-26	2233-2240	cannula	_	_	
16-27	2241-2243	in	_	_	
16-28	2244-2246	an	_	_	
16-29	2247-2256	assembled	_	_	
16-30	2257-2265	position	_	_	
16-31	2265-2266	.	_	_	

#Text=Other embodiments can use a rigid cannula of various materials.
17-1	2267-2272	Other	_	_	
17-2	2273-2284	embodiments	_	_	
17-3	2285-2288	can	_	_	
17-4	2289-2292	use	_	_	
17-5	2293-2294	a	_	_	
17-6	2295-2300	rigid	_	_	
17-7	2301-2308	cannula	_	_	
17-8	2309-2311	of	_	_	
17-9	2312-2319	various	_	_	
17-10	2320-2329	materials	_	_	
17-11	2329-2330	.	_	_	

#Text=The infusion cap comprises a lumen adapted to receive an elongate flexible tube.
18-1	2331-2334	The	_	_	
18-2	2335-2343	infusion	_	_	
18-3	2344-2347	cap	_	_	
18-4	2348-2357	comprises	_	_	
18-5	2358-2359	a	_	_	
18-6	2360-2365	lumen	_	_	
18-7	2366-2373	adapted	_	_	
18-8	2374-2376	to	_	_	
18-9	2377-2384	receive	_	_	
18-10	2385-2387	an	_	_	
18-11	2388-2396	elongate	_	_	
18-12	2397-2405	flexible	_	_	
18-13	2406-2410	tube	_	_	
18-14	2410-2411	.	_	_	

#Text=The infusion cap also comprises a hard cannula adapted to be inserted through the septum and to place said soft cannula in fluid communication with said lumen.
#Text=[0008] The base member is preferably circular, and the port preferably comprises a cylindrical portion extending from a first side of the base member.
19-1	2412-2415	The	_	_	
19-2	2416-2424	infusion	_	_	
19-3	2425-2428	cap	_	_	
19-4	2429-2433	also	_	_	
19-5	2434-2443	comprises	_	_	
19-6	2444-2445	a	_	_	
19-7	2446-2450	hard	_	_	
19-8	2451-2458	cannula	_	_	
19-9	2459-2466	adapted	_	_	
19-10	2467-2469	to	_	_	
19-11	2470-2472	be	_	_	
19-12	2473-2481	inserted	_	_	
19-13	2482-2489	through	_	_	
19-14	2490-2493	the	_	_	
19-15	2494-2500	septum	_	_	
19-16	2501-2504	and	_	_	
19-17	2505-2507	to	_	_	
19-18	2508-2513	place	_	_	
19-19	2514-2518	said	_	_	
19-20	2519-2523	soft	_	_	
19-21	2524-2531	cannula	_	_	
19-22	2532-2534	in	_	_	
19-23	2535-2540	fluid	_	_	
19-24	2541-2554	communication	_	_	
19-25	2555-2559	with	_	_	
19-26	2560-2564	said	_	_	
19-27	2565-2570	lumen	_	_	
19-28	2570-2571	.	_	_	
19-29	2572-2573	[	_	_	
19-30	2573-2577	0008	_	_	
19-31	2577-2578	]	_	_	
19-32	2579-2582	The	_	_	
19-33	2583-2587	base	_	_	
19-34	2588-2594	member	_	_	
19-35	2595-2597	is	_	_	
19-36	2598-2608	preferably	_	_	
19-37	2609-2617	circular	_	_	
19-38	2617-2618	,	_	_	
19-39	2619-2622	and	_	_	
19-40	2623-2626	the	_	_	
19-41	2627-2631	port	_	_	
19-42	2632-2642	preferably	_	_	
19-43	2643-2652	comprises	_	_	
19-44	2653-2654	a	_	_	
19-45	2655-2666	cylindrical	_	_	
19-46	2667-2674	portion	_	_	
19-47	2675-2684	extending	_	_	
19-48	2685-2689	from	_	_	
19-49	2690-2691	a	_	_	
19-50	2692-2697	first	_	_	
19-51	2698-2702	side	_	_	
19-52	2703-2705	of	_	_	
19-53	2706-2709	the	_	_	
19-54	2710-2714	base	_	_	
19-55	2715-2721	member	_	_	
19-56	2721-2722	.	_	_	

#Text=The introducer cap preferably comprises a hollow cylindrical portion extending from the second side of the introducer cap and located coaxially with the introducer needle.
20-1	2723-2726	The	_	_	
20-2	2727-2737	introducer	_	_	
20-3	2738-2741	cap	_	_	
20-4	2742-2752	preferably	_	_	
20-5	2753-2762	comprises	_	_	
20-6	2763-2764	a	_	_	
20-7	2765-2771	hollow	_	_	
20-8	2772-2783	cylindrical	_	_	
20-9	2784-2791	portion	_	_	
20-10	2792-2801	extending	_	_	
20-11	2802-2806	from	_	_	
20-12	2807-2810	the	_	_	
20-13	2811-2817	second	_	_	
20-14	2818-2822	side	_	_	
20-15	2823-2825	of	_	_	
20-16	2826-2829	the	_	_	
20-17	2830-2840	introducer	_	_	
20-18	2841-2844	cap	_	_	
20-19	2845-2848	and	_	_	
20-20	2849-2856	located	_	_	
20-21	2857-2866	coaxially	_	_	
20-22	2867-2871	with	_	_	
20-23	2872-2875	the	_	_	
20-24	2876-2886	introducer	_	_	
20-25	2887-2893	needle	_	_	
20-26	2893-2894	.	_	_	

#Text=The infusion cap preferably comprises a hollow cylindrical portion extending from the second side of the infusion cap and located coaxially with the hard cannula.
21-1	2895-2898	The	_	_	
21-2	2899-2907	infusion	_	_	
21-3	2908-2911	cap	_	_	
21-4	2912-2922	preferably	_	_	
21-5	2923-2932	comprises	_	_	
21-6	2933-2934	a	_	_	
21-7	2935-2941	hollow	_	_	
21-8	2942-2953	cylindrical	_	_	
21-9	2954-2961	portion	_	_	
21-10	2962-2971	extending	_	_	
21-11	2972-2976	from	_	_	
21-12	2977-2980	the	_	_	
21-13	2981-2987	second	_	_	
21-14	2988-2992	side	_	_	
21-15	2993-2995	of	_	_	
21-16	2996-2999	the	_	_	
21-17	3000-3008	infusion	_	_	
21-18	3009-3012	cap	_	_	
21-19	3013-3016	and	_	_	
21-20	3017-3024	located	_	_	
21-21	3025-3034	coaxially	_	_	
21-22	3035-3039	with	_	_	
21-23	3040-3043	the	_	_	
21-24	3044-3048	hard	_	_	
21-25	3049-3056	cannula	_	_	
21-26	3056-3057	.	_	_	

#Text=The first side of the infusion cap preferably is dome-shaped, and the infusion cap is preferably adapted to be rotatable relative to the base member when the infusion cap and the base member are assembled.
22-1	3058-3061	The	_	_	
22-2	3062-3067	first	_	_	
22-3	3068-3072	side	_	_	
22-4	3073-3075	of	_	_	
22-5	3076-3079	the	_	_	
22-6	3080-3088	infusion	_	_	
22-7	3089-3092	cap	_	_	
22-8	3093-3103	preferably	_	_	
22-9	3104-3106	is	_	_	
22-10	3107-3118	dome-shaped	_	_	
22-11	3118-3119	,	_	_	
22-12	3120-3123	and	_	_	
22-13	3124-3127	the	_	_	
22-14	3128-3136	infusion	_	_	
22-15	3137-3140	cap	_	_	
22-16	3141-3143	is	_	_	
22-17	3144-3154	preferably	_	_	
22-18	3155-3162	adapted	_	_	
22-19	3163-3165	to	_	_	
22-20	3166-3168	be	_	_	
22-21	3169-3178	rotatable	_	_	
22-22	3179-3187	relative	_	_	
22-23	3188-3190	to	_	_	
22-24	3191-3194	the	_	_	
22-25	3195-3199	base	_	_	
22-26	3200-3206	member	_	_	
22-27	3207-3211	when	_	_	
22-28	3212-3215	the	_	_	
22-29	3216-3224	infusion	_	_	
22-30	3225-3228	cap	_	_	
22-31	3229-3232	and	_	_	
22-32	3233-3236	the	_	_	
22-33	3237-3241	base	_	_	
22-34	3242-3248	member	_	_	
22-35	3249-3252	are	_	_	
22-36	3253-3262	assembled	_	_	
22-37	3262-3263	.	_	_	
